Acorda Therapeutics, Inc. Earnings Conference Call (Q4 2012)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Feb 13 Calls Today's Calls

Call Details Acorda Therapeutics, Inc. Earnings Conference Call (Q4 2012) Scheduled to start Wed, Feb 13, 2013, 8:30 am Eastern -- this event is ongoing now-- Listen to the ongoing live event audio stream About Acorda Therapeutics Inc (NasdaqGS:ACOR) Other Calls  Acorda Therapeutics, Inc., a biotechnology company, develops therapies for multiple sclerosis, spinal cord injury, and other nervous system disorders. Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with multiple sclerosis; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company’s pipeline also includes various products in development for the treatment, regeneration, and repair of the spinal cord and brain. Its preclinical products comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in multiple sclerosis, neuregulins/glial growth factor 2, and remyelinating antibodies; and chondroitinase program, which develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through specialty sales force, managed care team, and contract pharmaceutical telesales organizations. The company was founded in 1995 and is based in Hawthorne, New York. More Info: Quote | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings